Cargando…
Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma
Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus guideline for efficient and optimal workup of gliobl...
Autores principales: | Nasrallah, MacLean P., Binder, Zev A., Oldridge, Derek A., Zhao, Jianhua, Lieberman, David B., Roth, Jacquelyn J., Watt, Christopher D., Sukhadia, Shrey, Klinman, Eva, Daber, Robert D., Desai, Arati, Brem, Steven, O’Rourke, Donald M., Morrissette, Jennifer J. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537274/ https://www.ncbi.nlm.nih.gov/pubmed/31206012 http://dx.doi.org/10.1177/2374289519848353 |
Ejemplares similares
-
2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma
por: Schwab, Robert D., et al.
Publicado: (2018) -
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019) -
A dual-genotype oligoastrocytoma with histologic, molecular, radiological and time-course features
por: Nasrallah, Mac Lean P., et al.
Publicado: (2020) -
Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma
por: Wang, Sumei, et al.
Publicado: (2018) -
BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)